Transactions

Mergers & Acquisitions

H2-Pharma

Sale to ANI Pharmaceuticals

$10 million

February 2016

North America

PhosImmune

Sale to Agenus

$10 million upfront in cash & stock + up to $3

December 2015

North America

VistaPharm

Sale to Vertice Pharma (backed by Warburg Pincus)

November 2015

North America

XOMA

Sale of Biologics Manufacturing Facilities to Agenus

$5 million in cash and $1 million in Agenus stock

November 2015

North America

XOMA

Sale of Biodefense Program to Nanotherapeutics

November 2015

North America

IGI Laboratories

Acquisition of Alveda Pharmaceuticals

CAD$ 47 million

October 2015

North America

cCam Therapeutics

Sale to Merck

Up to $605 million

July 2015

Asia, Africa, MidEast, Latin America

Midatech Pharma

Acquisition of Dara Biosciences

Up to $30 million

June 2015

Europe

Ipsen

Acquisition of OctreoPharm Sciences

Up to €50 million

May 2015

Europe

Dr Reddy’s

Acquisition of US Rights for Trianex from CMP Pharma

March 2015

North America

PDI

Acquisition of Redpath Integrated Pathology

Up to $35 million

December 2014

North America

Innovative Therapies

Sale to Cardinal Health

Up to $65 million

September 2014

North America

Trimel

Acquisition of Canadian Rights to Estrace from Shire

$41 million

July 2014

North America

Ventrus Biosciences

Merger with Assembly Pharmaceuticals

May 2014

North America

Chelsea Therapeutics

Sale to Lundbeck

Up to $658 million

May 2014

North America

Fibrotech

Sale to Shire

$75 million upfront + milestones

May 2014

Asia, Africa, MidEast, Latin America

4-Antibody AG

Sale to Agenus

$40 million+ with $10mm upfront

January 2014

Europe

Semprae Laboratories

Sale to Innovus Pharmaceuticals

December 2013

North America

Pinnacle Biologics

Sale to Concordia Healthcare

December 2013

North America

Correvio

Sale to Cardiome

19.9% shares + $12mm

November 2013

Europe

Correvio

Sale of a privately held European pharmaceutical company

Correvio LLC, a privately held pharmaceutical company, was acquired by Cardiome Pharma Corp. Key benefits of the transaction include acceleration of Cardiome's launch of BRINAVESS™ (vernakalant IV) and its transformation into a global commercial organization positioned for future growth; Cardiome acquiring an EBITDA-positive, European, specialty pharmaceutical company selling Aggrastat® (tirofiban HCL) to cardiologists in over 60 countries worldwide with annual revenues of US$30+ million; brings together two highly complementary, in-hospital, intravenous, cardiology products sold through a direct sales force in Europe and via specialty distributors elsewhere; and reduces BRINAVESS build-out costs and shortens the time to profitability by providing an established operational and financial infrastructure with significant operating cost synergies. Under the terms of the agreement, Cardiome has acquired 100% of Correvio through the purchase of a combination of assets and shares of its subsidiaries in exchange for 19.9% of Cardiome’s outstanding shares (proforma ownership of approximately 16.6%) and a deferred cash consideration of US$12 M. The deferred cash consideration will be repaid monthly at an amount equal to 10% of cash receipts from product sales and any applicable interest accrued at 10% compounded annually. The adjusted deferred cash consideration must be repaid in full by December 1, 2019.

Press Release